T1	Participants 72 121	surgical patients with serious systemic infection
T2	Participants 285 325	patients with serious systemic infection
T3	Participants 327 429	Thirty-seven surgical patients were evaluated for efficacy and 46 patients were evaluated for toxicity
T4	Participants 1639 1689	patients who have serious infections after surgery
